ICMJE DISCLOSURE FORM							
Date:		3/15/2022	3/15/2022				
Your Name:		Robert Landewé	Robert Landewé				
Manuscript Title:			Wat betekenen de resultaten van de ORAL surveillance studie voor de behandeling van reumatoïde artritis met tofacitinib?				
Manuscript Number (if known):		nown):D6769	D6769				
In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so. The author's relationships/activities/interests should be defined broadly. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript. In item #1 below, report all support for the work reported in this manuscript without time limit. For all other items, the time frame for disclosure is the past 36 months.							
		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)				
	Time frame: Since the initial planning of the work						
1	All support for the present	None					

	elationship or indicate none (add rows as needed) made to you or to your institution)			
Time frame: Since the initial planning of the work				
All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	Click the tab key to add additional rows.			
Grants or				
contracts from				
any entity (if not indicated in item				
#1 above).				
3 Royalties or ⊠ None				
licenses				
1 1 1 1 1 1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item. Grants or contracts from any entity (if not indicated in item #1 above).	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item. Time frame: past 36 months Solution of study materials, medical writing, article processing charges, etc.) No time limit for this item. Time frame: past 36 months None None None		

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
4	Consulting fees	□ None AbbVie, BMS, Gilead, Galapagos, GSK, Janssen, Lilly, Novartis, Pfizer, UCB	
5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events	□ None AbbVie, BMS, Gilead, Galapagos, GSK, Janssen, Lilly, Novartis, Pfizer, UCB	
6	Payment for expert testimony	None	
7	Support for attending meetings and/or travel	None None	
8	Patents planned, issued or pending	None	
9	Participation on a Data Safety Monitoring Board or Advisory Board	□ None	
10	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	None None	

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)	
11	Stock or stock options	None		
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	None		
13	Other financial or non-financial interests	□ None Director of Rheumatology & Consultancy, B.V.		
Please place an "X" next to the following statement to indicate your agreement: □ I certify that I have answered every question and have not altered the wording of any of the questions on this form.				